Lafeuille Marie-Hélène, Duh Mei Sheng, Zhang Jie, Wertz Debra, Gu Tao, Swensen Andrine, Lefebvre Patrick
Groupe d'analyse, Ltée, Montréal, QC, Canada.
J Asthma. 2011 Nov;48(9):923-30. doi: 10.3109/02770903.2011.618568. Epub 2011 Oct 7.
Omalizumab (Xolair®) is a monoclonal antibody indicated for moderate to severe persistent allergic asthma patients with symptoms that are inadequately controlled with inhaled corticosteroids (ICS).
This study describes concomitant asthma medication use in patients treated with omalizumab.
An analysis of health insurance claims from MarketScan (2002-2009), Medicaid (2002-2009), and the HealthCore Integrated Research Database (HIRD™) (2002-2010) was conducted. Medical charts were also extracted for a subset of HIRD patients. Patients aged ≥12 years and newly initiated on omalizumab with 12 months of continuous insurance coverage prior to the first omalizumab dispensing (baseline period) and ≥2 asthma claims were included. Concomitant asthma medication use was summarized in eight medication classes.
A total of 6038 patients were identified (Medicaid: 731; MarketScan: 3521; HIRD: 1786). A high proportion of new omalizumab users had an asthma-related emergency room visit (Medicaid: 34%; MarketScan: 17%; HIRD: 16%) or hospitalization (Medicaid: 36%; MarketScan: 14%; HIRD: 21%) within 12 months prior to initiating omalizumab. Most patients (Medicaid: 96%; MarketScan: 89%; HIRD: 86%) received three concomitant asthma medication classes or more during the baseline period. Concomitant ICS use was observed in 95%, 89%, and 86% of Medicaid, MarketScan, and HIRD patients, respectively. In HIRD patients without evidence of receiving other asthma medication prior to omalizumab, 17 out of 20 patients had a documented baseline history of asthma-related medication use in their medical charts.
This large observational study using health insurance claims from three databases and confirming results from medical charts provides evidence that nearly all omalizumab users had received other asthma medications prior to initiating omalizumab.
奥马珠单抗（Xolair®）是一种单克隆抗体，适用于吸入性糖皮质激素（ICS）治疗症状控制不佳的中重度持续性过敏性哮喘患者。
本研究描述了接受奥马珠单抗治疗的患者同时使用的哮喘药物情况。
对MarketScan（2002 - 2009年）、医疗补助计划（2002 - 2009年）和HealthCore综合研究数据库（HIRD™）（2002 - 2010年）中的医疗保险理赔数据进行分析。还提取了一部分HIRD患者的病历。纳入年龄≥12岁、首次使用奥马珠单抗前有12个月连续保险覆盖（基线期）且有≥2次哮喘理赔记录的患者。同时使用的哮喘药物按八类药物进行汇总。
共识别出6038例患者（医疗补助计划：731例；MarketScan：3521例；HIRD：1786例）。很大一部分新使用奥马珠单抗的患者在开始使用奥马珠单抗前12个月内有哮喘相关的急诊就诊（医疗补助计划：34%；MarketScan：17%；HIRD：16%）或住院治疗（医疗补助计划：36%；MarketScan：14%；HIRD：21%）。大多数患者（医疗补助计划：96%；MarketScan：89%；HIRD：86%）在基线期同时使用三类或更多类哮喘药物。医疗补助计划、MarketScan和HIRD患者中分别有95%、89%和86%同时使用ICS。在HIRD患者中，20例在使用奥马珠单抗前无使用其他哮喘药物证据的患者中，有17例在其病历中有哮喘相关药物使用的记录基线史。
这项使用来自三个数据库的医疗保险理赔数据并通过病历证实结果的大型观察性研究提供了证据，表明几乎所有奥马珠单抗使用者在开始使用奥马珠单抗之前都接受过其他哮喘药物治疗。
